Essais liés2clinical trials
VilleKassellocalisation
PaysGermanylocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06047444

Ouvrir le site du centre

Essais cliniques associés

2
MoléculeIndication / populationPhaseNCTTitreStatut
Rimegepant 75mg daily dosing Migraine Phase 4 NCT05217927 Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens COMPLETED
Botulinum toxin type A Migraine Phase 3 NCT06047444 C-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults ACTIVE_NOT_RECRUITING